Infectious Diseases News and Research RSS Feed - Infectious Diseases News and Research

Rising number of malaria deaths likely to exceed total number of Ebola deaths

Rising number of malaria deaths likely to exceed total number of Ebola deaths

Around 74000 fewer malaria cases than expected were seen at health facilities in Guinea in 2014 compared with pre-Ebola years, new research published in The Lancet Infectious Diseases journal has found. [More]
BiondVax Pharmaceuticals declares closing of over-allotment option granted to underwriters

BiondVax Pharmaceuticals declares closing of over-allotment option granted to underwriters

​BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced the closing of an additional and partial exercise of the over-allotment option granted to the underwriters. [More]
New research examines antibiotic choice for treating children with community-acquired pneumonia

New research examines antibiotic choice for treating children with community-acquired pneumonia

New Vanderbilt-led research shows hospitals are doing a better job of using antibiotics less commonly associated with antibiotic resistance to treat children hospitalized with community-acquired pneumonia (CAP). [More]
VG Life Sciences receives U.S. patent for combination cancer therapy

VG Life Sciences receives U.S. patent for combination cancer therapy

VG Life Sciences, Inc., a biotechnology company developing therapies for cancer, autoimmune and infectious diseases, announced that the U.S. Patent and Trademark Office will issue Patent No. 9073985 covering VGLS' combination therapy for treating drug-resistant cancer by combining an autophagy inhibitor with a chemotherapy drug. [More]
Vaxil's ImMucin receives FDA orphan drug designation for treatment of multiple myeloma

Vaxil's ImMucin receives FDA orphan drug designation for treatment of multiple myeloma

Vaxil Bio, a company specializing in the development of immunotherapy-based drugs, reports today that its lead product, ImMucin, has been granted an "orphan drug" designation by the US Food and Drug Administration, for the treatment of multiple myeloma (MM). [More]
Planning for first clinical trial of MERS-CoV vaccine candidate now underway

Planning for first clinical trial of MERS-CoV vaccine candidate now underway

Researchers from Ludwig-Maximilians-Universitaet in Munich have demonstrated, in a preclinical setting, the protective effect of a candidate vaccine directed against the coronavirus that causes Middle East Respiratory Syndrome. Planning for the first clinical trial is now underway. [More]
Pediatric study looks at evidence-based predictors of biphasic allergic reactions

Pediatric study looks at evidence-based predictors of biphasic allergic reactions

Children are more likely to have a repeat, delayed anaphylactic reaction from the same allergic cause, depending on the severity of the initial reaction. The first pediatric study to look at the predictors for this phenomenon was published today in Annals of Allergy, Asthma & Immunology. [More]
Human breast milk bought online poses serious health risks

Human breast milk bought online poses serious health risks

The recent craze for human breast milk, which has become a lucrative online market, poses serious health risks, according to British experts. [More]
Three studies describe advances toward development of antibodies to stop HIV

Three studies describe advances toward development of antibodies to stop HIV

A trio of studies being published today in the journals Science and Cell describes advances toward the development of an HIV vaccine. The three study teams all demonstrated techniques for stimulating animal cells to produce antibodies that either could stop HIV from infecting human cells in the laboratory or had the potential to evolve into such antibodies. [More]
International researchers identify previously unknown genetic immunodeficiency

International researchers identify previously unknown genetic immunodeficiency

An analysis of five families has revealed a previously unknown genetic immunodeficiency, says an international team led by researchers from Boston Children's Hospital. The condition, linked to mutations in a gene called DOCK2, deactivates many features of the immune system and leaves affected children open to a unique pattern of aggressive, potentially fatal infections early in life. [More]
Nucleoporin proteins play significant role in maintaining embryonic stem cells

Nucleoporin proteins play significant role in maintaining embryonic stem cells

What if you found out that pieces of your front door were occasionally flying off the door frame to carry out chores around the house? That's the kind of surprise scientists at the Salk Institute experienced with their recent discovery that nucleoporins -- proteins that act as cellular 'doorways' to help manage what goes in and out of a cell's nucleus -- are actually much bigger players in expressing genes than previously thought. [More]
Key lessons from Middle East Respiratory Syndrome outbreak in South Korea

Key lessons from Middle East Respiratory Syndrome outbreak in South Korea

The outbreak of Middle East Respiratory Syndrome (MERS) in South Korea is the subject of a fast-tracked editorial in the International Journal of Infectious Diseases, written by Dr. Eskild Petersen and colleagues. [More]
Single difference in HIV's genetic code influences progression of disease

Single difference in HIV's genetic code influences progression of disease

In a finding that furthers the understanding of human immunodeficiency virus (HIV), researchers from Children's Hospital Los Angeles discovered two locations where a single difference in HIV's genetic code altered the way the virus infected the cell, thereby influencing the progression of the disease. [More]
New study launched in Liberia to better understand health consequences of Ebola virus disease

New study launched in Liberia to better understand health consequences of Ebola virus disease

The Liberia-U.S. clinical research partnership known as PREVAIL has launched a study of people in Liberia who have survived Ebola virus disease (EVD) within the past two years. The study investigators hope to better understand the long-term health consequences of EVD, determine if survivors develop immunity that will protect them from future Ebola infection, and assess whether previously EVD-infected individuals can transmit infection to close contacts and sexual partners. [More]
NIH-funded study identifies DOCK2 deficiency

NIH-funded study identifies DOCK2 deficiency

Researchers funded by the National Institutes of Health have identified a new immune disorder--DOCK2 deficiency--named after the mutated gene responsible for the disease. [More]
FDA accepts BiondVax's IND for Multimeric-001 vaccine

FDA accepts BiondVax's IND for Multimeric-001 vaccine

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced that its Investigational New Drug Application (IND) for its Multimeric-001 vaccine (M-001), has been accepted by the US Food and Drug Administration, and the Company was notified by its regulatory advisors that the 'study may proceed'. [More]
Regulatory T cells critical for the immune system's ability to fight off future pathogen attacks

Regulatory T cells critical for the immune system's ability to fight off future pathogen attacks

Just as militaries need to have trained, experienced soldiers ready for future wars, making sure that the immune system has enough battle-ready T cells on hand is important for fast-acting, more effective vaccines, according to Penn State researchers. [More]
CINtec PLUS Cytology test more effective than HC2 HPV test in identifying women with precancerous lesions

CINtec PLUS Cytology test more effective than HC2 HPV test in identifying women with precancerous lesions

Ventana Medical Systems, Inc., a member of the Roche Group, today announced the publication of further results from the Primary ASC-US LSIL Marker Study (PALMS) in this month's issue of Cancer Cytopathology. The PALMS study, which enrolled more than 27,000 women from five European countries, was designed to evaluate the diagnostic performance of the CINtec PLUS Cytology test in detecting pre-cancerous cervical disease compared to HPV testing and more traditional screening methods like Pap cytology. [More]
BiondVax invited to present at EDUFULVAC-NIAID workshop on immunoassay standardization for universal flu vaccines

BiondVax invited to present at EDUFULVAC-NIAID workshop on immunoassay standardization for universal flu vaccines

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases,today announced that it has been invited to present in a workshop organized by EDUFULVAC, (EDUcate inFLUenza VACcine) a corresponding European Consortium coordinated by the European Vaccine Initiative (Germany) and NIAID (the National Instituteof Allergy and Infectious Diseases, a National Institute of Health branch) in the United States. [More]
DSM Sinochem Pharmaceuticals supports WHO’s ‘Call to Action’ on antimicrobial resistance

DSM Sinochem Pharmaceuticals supports WHO’s ‘Call to Action’ on antimicrobial resistance

Following the Global Health Summit in Uppsala (Sweden) on 2-3 June, 2015, DSM Sinochem Pharmaceuticals pledged its commitment to the WHO’s ‘Call to Action’ on antimicrobial resistance issued at the Summit. One of the biggest opportunities to maintain the effectiveness and availability of antibiotics is responsible waste management, to date a highly undervalued dimension in the debate around resistance. DSP promised to use its expertise and influence in this area to help curb antimicrobial resistance. [More]
Advertisement
Advertisement